The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults

Product not yet rated

Includes a Live Event on 09/24/2020 at 1:00 PM (EDT)


Back to Package

image

The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults


This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

Adolescents and young adults present for treatment with a broad spectrum of opioid use disorder severity with a range of co-occurring medical and psychiatric illnesses. The treatment of youth with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents and young adults often benefit from services designed specifically for them. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

Session Information 

Date: Tuesday, September 24, 2020

Time: 1:00 pm ET / 12:00 pm CT/ 10:00 am PT

Speaker(s): Marc Fishman, MD

Learning Objectives 

By completing this webinar, you will be able to:

  1. Summarize the guideline’s treatment recommendations for adolescents and young adults with OUD and discuss how they should be used in practice. 
  2. Identify the fundamental components of an OUD patient assessment and diagnosis for adolescents and young adults.
  3. Recognize the unique needs and treatment recommendations for adolescents and young adults

Marc Fishman

MD

Marc Fishman MD is a specialist in  addiction psychiatry and addiction medicine.  He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and a current memeber of its Board.

ACCME Accredited with Commendation

CME/CE Credits

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification (MOC)

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

ABA Maintenance of Certification (MOC)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

ABP Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

 ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABAM Transitional Maintenance of Certification (Tmoc)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

Program Planning Committee, CME Committee, Medical Education Council (MEC)

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

ASAM CME Committee Reviewer

Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

Faculty & Planning Committee Disclosures

Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


Key:

Complete
Failed
Available
Locked
The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents and Young Adults
09/24/2020 at 1:00 PM (EDT)   |  60 minutes
09/24/2020 at 1:00 PM (EDT)   |  60 minutes This live webinar will be hosted on Tuesday, September 24, 2020 1:00 pm EDT.
CME Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Credit & Certificate
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available This session has been approved for 1 AMA PRA Category 1 Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.